The Cocktail Report (sound really smart around your friends):
Between 10 and 15 percent of people who have heart attacks have none of the four classic risk factors: high LDL, hypertension, smoking, or diabetes. Research from Brigham and Women's Hospital cardiologist Paul Ridker now points to chronic inflammation as the missing variable that explains this gap.
The mechanism centers on the NLRP3 inflammasome (a protein complex inside immune cells that acts as an alarm system) and its downstream molecule IL-1β (interleukin-1 beta, a signaling protein that triggers widespread inflammation). Crystallized cholesterol and uric acid deposits in artery walls appear to trigger this alarm, which drives plaque formation independently of LDL levels.
The landmark CANTOS trial, published in the New England Journal of Medicine in 2017, enrolled nearly 10,000 heart disease patients with high CRP (C-reactive protein, a blood marker of inflammation). Those given canakinumab (a monoclonal antibody targeting IL-1β) had 15 percent fewer cardiac events than those given a placebo, even though their cholesterol levels were unchanged.
A more accessible anti-inflammatory drug, colchicine (an old gout remedy now repurposed), reduced cardiac events by a similar margin in the CLEAR SYNERGY trial published in 2025. The FDA declined to approve it for this use in 2023 due to gastrointestinal side effects and ongoing trial concerns, though research continues.
CRP testing is inexpensive and widely available. People with low LDL but high CRP appear to benefit substantially from statins, not because statins lower cholesterol in those patients but because statins also have anti-inflammatory effects.
If you have ever wondered why a fit, non-smoking person with normal cholesterol had a heart attack, this article is for you. The explanation that has dominated cardiology for 50 years, that cholesterol clogs arteries like fat down a pipe, turns out to be incomplete in a way that has cost lives.
The more complete picture involves the immune system: when crystallized cholesterol or uric acid deposits lodge in artery walls, the body treats them as foreign invaders and launches an inflammatory response. That response, sustained over years, is what drives plaque to rupture and cause heart attacks.
The CANTOS trial was the pivotal proof: nearly 10,000 patients with a prior heart attack and elevated CRP were enrolled, and those given a drug targeting IL-1β had significantly fewer future cardiac events, with no change in their cholesterol levels. That result directly demonstrated that inflammation drives risk independently of lipids.
To be candid, this is still a competing framework, not a settled replacement for the lipid model. Most cardiologists view inflammation and LDL as co-drivers, with inflammation being an additional, underdiagnosed variable that statins alone do not fully address.
Readers of Article 024 will recognize the NLRP3 inflammasome mechanism, which BGE-102 specifically targets. This article covers the broader case for inflammation as a cardiovascular driver, while Article 024 focused on one cutting-edge drug within that framework.
For you personally, the actionable takeaway is simple and inexpensive: ask your doctor for a high-sensitivity CRP (hsCRP) test alongside your standard lipid panel. It costs roughly $10 to $30 and is not routinely ordered, but if your LDL is normal and your CRP is elevated, anti-inflammatory strategies may be the more relevant intervention for your specific risk profile.
Why Should You Care?
The standard cardiac risk panel most people receive does not include CRP, which means a meaningful percentage of people at elevated risk are told their numbers look fine. The research covered in this Scientific American cover story suggests that a $10 blood test could change that picture, and that anti-inflammatory drugs already in clinical trials may represent the next major advance in cardiovascular medicine.
Sources:
Wenner Moyer M. Your Heart in Flames. Scientific American. May 2026, pp. 28-33.
Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease (CANTOS). N Engl J Med. 2017;377:1119-1131. https://www.nejm.org/doi/full/10.1056/NEJMoa1707914
Jolly SS, et al. Colchicine in Acute Myocardial Infarction (CLEAR SYNERGY). N Engl J Med. 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2304876
Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER). N Engl J Med. 2008. https://www.nejm.org/doi/full/10.1056/NEJMoa0807646
